Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control (FIMARO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02913794
Recruitment Status : Unknown
Verified September 2016 by Boryung Pharmaceutical Co., Ltd. Recruitment status was: Recruiting
A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments
Actual Study Start Date :
October 11, 2016
Estimated Primary Completion Date :
March 30, 2018
Estimated Study Completion Date :
March 30, 2018
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
19 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration
Patients being hospitalized
Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
Patients who have more than 400mg/dl triglyceride(TG) at the registration time